

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2). Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	AFT Pharmaceuticals Limited (AFT)
Date this disclosure made:	19-Jun-17
Date of last disclosure:	25-May-17
Director or senior manager giving disclosure	
Full name(s):	John Douglas Wilson
Name of listed issuer:	AFT Pharmaceuticals Limited (AFT)
Name of related body corporate (if applicable):	Not applicable
Position held in listed issuer:	Director
Cummany of convinition or disposal of valouant interest (evaluding appointed devivative	201
Summary of acquisition or disposal of relevant interest (excluding specified derivative Class of affected quoted financial products:	Fully-Paid Ordinary Shares in AFT
Class of affected quoted finalicial products.	Beneficial interest as beneficiary of trust.
Nature of the affected relevant interest(s):	Power to control the exercise of the right to vote as director and shareholder of Gillespie Nominee Limited.
For that relevant interest-	
Number held in class before acquisition or disposal:	50,022
Number held in class after acquisition or disposal:	56,689
Current registered holder(s):	Gillespie Nominees Limited as Trustee of the AJJD Trust
Registered holder(s) once transfers are registered:	Gillespie Nominees Limited as Trustee of the AJJD Trust
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	1
Details of transactions requiring disclosure-	
Date of transaction:	16-Jun-17
Nature of transaction:	Allotment of new Ordinary Shares pursuant to Share Purchase Plan
Name of any other party or parties to the transaction (if known):	Not applicable
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a	
cash value, describe the consideration:	NZ\$2.25 per share
Number of financial products to which the transaction related:	6,667
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to	
proceed during the closed period:	Not applicable
Date of the prior written clearance (if any):	Not applicable
Summary of other relevant interests after acquisition or disposal:	Net emiliable
Class of quoted financial products: Nature of relevant interest:	Not applicable Not applicable
For that relevant interest,-	Not applicable
Number held in class:	Not applicable
Current registered holder(s):	Not applicable
For a derivative relevant interest,-	That applicable
Type of derivative:	Not applicable
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial	
products (if any):	Not applicable
A statement as to whether the derivative is cash settled or physically settled:	Not applicable
Maturity date of the derivative (if any):	Not applicable
Expiry date of the derivative (if any):	Not applicable
The price's specified terms (if any):	Not applicable
Any other details needed to understand how the amount of the consideration payable	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	Not applicable
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: For that derivative relevant interest,-	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	Not applicable Not applicable

Certification	
I certify that, to the best of my knowledge and belief, the information contained in this	
disclosure is correct and that I am duly authorised to make this disclosure by all persons	
for whom it is made.	- nA
Signature of director or officer:	"PHAL
orginatare of amount of ornicor.	WILL
Date of signature:	19-Jun-17